###### Strengths and limitations of this study

-   Use of an extensive search strategy and adherence to predetermined inclusion/exclusion criteria.

-   Use of evidence-based inverse variance weighted random effects meta-analysis to quantify a robust estimate of the pooled frequency of heterozygous familial hypercholesterolaemia in adults.

-   Our study possesses a large sample size (n=2 458 456).

-   We include only English-language peer-reviewed studies making it possible that some relevant articles were not included.

-   Our analyses possessed considerable amount of quantifiable heterogeneity.

Background {#s1}
==========

The frequency of heterozygous familial hypercholesterolaemia (FH) was originally reported as 1 in 500 (0.2%).[@R1] This estimate is based on work that determined the prevalence in homozygous individuals and used Hardy-Weinberg principles to calculate the frequency in heterozygotes.[@R2] Similar frequencies have been described in subsequent reports of population-based samples.[@R3] However, this estimate has recently been criticised for its imprecision.[@R8] Human behaviour does not adhere to Hardy-Weinberg assumptions (eg, random mating, no migration) and violations of these principles have been shown to significantly impact the results of gene-disease association studies.[@R9] Further, recent work indicates as many as 1 in 200 people may be affected by FH[@R10] and there are some data to suggest that regional variations in FH frequency exist.[@R13]

The population prevalence of FH is difficult to determine for several reasons. Most countries lack national FH registers or large observational databases. Yet, even when such databases exist, they often contain insufficient data on aspects of clinical histories essential for FH diagnosis. No uniform criteria for FH diagnosis exist and the three sets of criteria commonly used vary in the amount of emphasis placed on clinical characteristics in determining FH. Additionally, the ability to detect such findings may vary based on the clinical acumen and experiences of assessors.[@R20] Genetic diagnosis has the potential to mitigate confounding inherent in clinical diagnostic criteria. However, the feasibility and cost-effectiveness of genetic screening continues to be debated,[@R8] a high proportion of patients with clinical FH diagnoses may not be identified[@R24] and all of the genetic mutations that cause FH may not yet be known. Together, these factors suggest the potential for a different FH frequency than original estimates.

Ascertaining the prevalence of FH has important clinical and public health implications, especially in light of the availability of new but expensive treatments (eg, proprotein convertase subtilisin/kexin type 9 (PCKS9) inhibitors) for this condition. FH is caused by defects in the low-density lipoprotein receptor (LDLR) pathway, resulting in elevated LDL-cholesterol (LDL-C) concentrations that are largely resistant to caloric restriction, weight loss and physical exercise interventions in affected individuals.[@R24] FH also predicts a very high risk of cardiovascular disease (CVD) even in the absence of other traditional risk factors as patients possess these LDL-C concentrations from birth.[@R25] Early diagnosis and treatment of FH with lipid-lowering therapy has proven to be both cost efficient and effective in mitigating cardiovascular morbidity and mortality risk.[@R26] Despite these benefits, numerous reports suggest that FH is currently underdiagnosed in the general population[@R27] and that in some jurisdictions, a large proportion of affected individuals have difficulty accessing effective lipid-lowering therapies.[@R28] Clinicians routinely consider estimates of disease prevalence, variations in different population groups (eg, age, sex, ethnicity) and the presence of known risk factors in formulating differential diagnoses. These factors also form important considerations when evaluating national strategies for the optimal identification and treatment of individuals.[@R29] Thus, determining the prevalence of FH and its variation by sociodemographic factors provides an important first step in reducing disease burden.

While a number of narrative and systematic reviews have summarised studies of FH,[@R8] there has been no attempt to consolidate these studies to derive a robust prevalence estimate or to assess variation according to sociodemographic factors. We therefore aimed to systematically review the existing literature presenting estimates of FH in the adult general population and explore variation in prevalence estimates by age, sex, geographical location and study quality.

Methods {#s2}
=======

We carried out a systematic review and meta-analysis in accordance with the Meta-analysis Of Observational Studies in Epidemiology consensus statement.[@R35] The protocol for this review was registered with the PROSPERO International Prospective Register of Systematic Reviews (CRD42016042208).

Study identification and selection {#s2a}
----------------------------------

This study was part of a series of systematic reviews with a standardised search strategy examining the disease burden posed by heterozygous FH. We searched MEDLINE, EMBASE, PsycINFO, Global Health, the Cochrane Library and Pubmed (for publications ahead of print) for published, peer-reviewed literature using controlled vocabulary and keywords related to FH and relevant epidemiological terms. Results were limited to human studies published in English between 1 January 1990 and 31 January 2017. We reviewed reference lists of all included articles and relevant literature reviews, systematic reviews and meta-analyses for additional eligible studies. A detailed search strategy is included in the supplement to this manuscript (see online [supplementary etable 1](#SP1){ref-type="supplementary-material"}).
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Titles and abstracts and full texts were evaluated in duplicate by independent reviewers (LEA, SDS) using standardised forms (see online [supplementary etable 2](#SP1){ref-type="supplementary-material"}). Disagreements were resolved through discussion to consensus. For inclusion in the systematic review of prevalence, studies were required to include live human participants and to report on the prevalence of FH. Studies were included if they ascertained FH frequency using one of the following methods (see online [supplementary etables 3--5](#SP1){ref-type="supplementary-material"}): (1) DNA-based evidence of LDLR, apolipoprotein-B (Apo B), or PCSK9 mutations; (2) Dutch Lipid Clinic Network (DLCN) criteria; (3) Simon Broome Registry (SBR) criteria; (4) Making Early Diagnosis to Prevent Early Death (MEDPED) criteria or (5) total cholesterol levels (\>290 mg/dL or 7.5 mmol/L) or LDL-C levels (\>189 mg/dL or 4.9 mmol/L).[@R34] We did not include articles reporting on the prevalence of or regional variations in specific LDLR, Apo B or PCSK9 mutations in study populations given their potential to underestimate FH frequencies.

Data extraction {#s2b}
---------------

One reviewer (LEA) independently extracted data regarding study characteristics (eg, design, population characteristics, diagnostic measures, prevalence estimates) from the full text of included articles. Another reviewer (RLR) checked the extracted data and any detected discrepancies were resolved. We did not attempt to contact authors of studies with missing or incomplete data nor did we exclude any such studies from our synthesis.

Study quality assessment {#s2c}
------------------------

Two reviewers (LEA, RLR) independently assessed the quality of eligible studies using the Effective Public Health Practice Project (EPHPP) Quality Assessment Tool for Quantitative Studies (<http://www.ephpp.ca/tools.html>) and resolved discrepancies through consensus. It has been shown to be acceptable for use in evaluating a variety of study designs including randomised controlled trials, before-and-after studies and case control studies (see online [supplementary etable 6](#SP1){ref-type="supplementary-material"}). The tool assesses study quality across six domains: selection bias; study design; confounding variables; blinding protocols; data collection methods and handling of withdrawals and dropouts. Each dimension is rated on a three-point scale---strong, moderate and weak---and these ratings feed into a global rating of study quality. Global study quality is considered to be strong if none of the quality domains is rated as weak, moderate if one domain is rated as weak and weak if two or more domains are rated as weak.

Data synthesis {#s2d}
--------------

Our primary analysis consisted of a pooled estimate of prevalence across all studies using a random effects model.[@R36] We also pooled data from studies separately under the model in order to calculate the pooled prevalence of FH in children (ages 0--19) and adults (\>20 years of age). Where studies presented multiple diagnostic criteria, estimates derived from genetic testing were used in the analysis as this was thought to provide a more conservative estimate. Where studies derived estimates using DLCN criteria, we pooled reported cases of 'definite' or 'probable' FH to determine individual study estimates. Similarly, 'definite' or 'possible' FH diagnoses using Simon Broome criteria were pooled in the meta-analyses. Where multiple studies reported prevalence estimates from a single cohort, estimates were taken from the paper reporting the largest sample and the other paper excluded from the analysis. Potential influences on prevalence estimates were investigated using subgroup analyses and meta-regression. Where studies allowed, we descriptively compared prevalence estimates by age, sex, prevalence estimation method, study quality and geographical location within studies. We then assessed the influence of these factors on variation in the estimated prevalence using meta-regression models.

### Statistical analysis {#s2d1}

We calculated pooled prevalence figures with 95% CIs using the DerSimonian and Laird random effects model.[@R37] In meta-analyses of prevalence using inverse variance methods, when the frequency estimate of a single study approaches the limits of prevalence (ie, 0% or 100% of the population), the variance for that study moves toward 0, leading to the resulting weight in the meta-analysis being overestimated.[@R36] To accommodate for this, we conducted the meta-analysis with prevalence estimates that had been transformed using the double arcsine method.[@R36] The final pooled result and 95% CIs were then back transformed and expressed as percentages for ease of interpretation. We assessed heterogeneity in our pooled analyses using the I^2^ statistic as it is not sensitive to the scale of effect size or the total number of studies included in the meta-analysis.[@R38] Finally, publication bias was examined formally using Egger's weighted regression, with significance set at p\<0.10.[@R39] Publication bias was also assessed visually using Begg's funnel plot as well as a *Doi* plot.[@R40] If publication bias was present, we used the trim and fill method to adjust for publication bias.[@R40] Analyses were performed using the MetaXL add-in for Microsoft Excel (<http://www.epigear.com>). Forest plots were generated using DistillerSR Forest Plot Generator from Evidence Partners (<https://www.evidencepartners.com/resources/forest-plot-generator/>).

Meta-regression was used to discern the influence of age, sex, prevalence estimation method, study quality, geographical location, year of publication and study setting (ie, electronic health records versus general population registers) on our pooled prevalence estimate. We used Stata V.13.1 to perform the meta-regression analysis on the log scale of the back transformed effect size (ie, prevalence), with each trial weighting equal to that derived under the random effects model and between study variance estimated with the restricted maximum likelihood method. The log of the pooled prevalence estimate was used as the dependent variable whereas sample size, study quality scores, mean sample age and study proportions of female participants were used as continuous predictive variables. Categorical covariates such as prevalence estimation method and geographical location were dummy-coded and examined through a joint test for all dummy-coded covariates.

### Sensitivity analyses {#s2d2}

We conducted additional analyses to assess the robustness of our pooled prevalence estimate. We examined the impact of time on the diagnosis of FH by sequentially excluding studies published before the year 2000 and 2010. We also assessed the impact of study setting by comparing estimates derived from population-based databases with those in patient cohorts (ie, community clinics, patient registries, electronic health records). Finally, we excluded studies using LDL-C to diagnose FH as well as those from countries with known founder populations as both were likely to result in a higher pooled frequency.

Results {#s3}
=======

Study selection {#s3a}
---------------

Our search identified 4153 citations, of which 3574 were unique. After applying our inclusion and exclusion criteria, 90 articles progressed to screening at the full-text level, of which 21 articles were included in this review. The flow of included studies is presented in [figure 1](#F1){ref-type="fig"}.

![Flow of studies included in systematic review of heterozygous familial hypercholesterolaemia prevalence. FH, familial hypercholesterolaemia.](bmjopen-2017-016461f01){#F1}

Characteristics of included studies {#s3b}
-----------------------------------

Twenty-one studies estimating point prevalence of FH were included in this review ([table 1](#T1){ref-type="table"}). The majority of these studies were European (n=9), while others were conducted in North America (n=4), Asia (n=2), Australia (n=3) and Africa (n=1). Two of the studies pooled data from international cohorts.[@R10] Combined, they represented data from 28 countries across four continents. Studies representing multiple countries included data from coronary artery disease[@R10] and dyslipidaemia cohorts.[@R42] FH is overexpressed among those with coronary heart disease as well as statin-treated individuals.[@R24] For these reasons, we elected against pulling country-specific data from these papers. Among all included studies, females comprised between 26.4% and 55.0% of the total sample. Four studies diagnosed FH using DLCN criteria,[@R42] three studies used genetic sequencing,[@R46] three studies used LDL-C measurements,[@R49] one study used SBR criteria[@R7] and one employed MEDPED criteria.[@R6] Another four included studies reported prevalence estimates using more than one method for comparison.[@R10] Prevalence estimates reported in individual studies ranged from 0.05% (95% CI 0.05% to 0.06%) to 5.62% (95% CI 5.44% to 5.79%). When evaluated by the EPHPP tool, most studies were rated as being moderate (n=7) or strong (n=13) in quality. On EPHPP domains, studies were most likely to receive weak ratings due to a low likelihood of representing the general population, a failure to account for missing participant data or adjust for relevant confounders (see online [supplementary etable 7](#SP1){ref-type="supplementary-material"}).

###### 

Characteristics of studies included in systematic review of FH prevalence

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study author (publication year)                      Country                Data source(s)                                      Enrolment period (years)   Diagnostic criteria   Sample size              Age (years)         Female, N (%)     FH cases, N   Prevalence estimate (95% CI)\*   Study quality
  ---------------------------------------------------- ---------------------- --------------------------------------------------- -------------------------- --------------------- ------------------------ ------------------- ----------------- ------------- -------------------------------- ---------------
  **Studies reporting on FH prevalence in adults**                                                                                                                                                                                                                                               

  Abdul-Husn *et al *(2016)[@R54]                      USA                    Geisinger Health System EHR                         NR                         DNA                   50 726                   18+                 30 334 (59.8%)    229           0.45% (0.40% to  0.51%)          ★★★

  Benn *et al *(2012)[@R11]                            Denmark                Copenhagen General Population Study                 2003+                      DLCN                  69 016                   20--100             37 959 (55.0%)    502           0.73% (0.67% to 0.79%)           ★★★

  DNA                                                  60 710                 20                                                  0.03% (0.02% to  0.04%)                                                                                                                                        

  SBR                                                  69 016                 2830                                                4.10% (3.95% to  4.25%)                                                                                                                                        

  MEDPED                                               69 016                 552                                                 0.80% (0.73% to 0.87%)                                                                                                                                         

  Benn *et al *(2016)[@R52]                            Denmark                Copenhagen General Population Study                 2003+                      DLCN                  98 098                   20--100             53 958 (55.0%)    341           0.35% (0.31% to 0.39%)           ★★★

  DNA                                                  98 098                 174                                                 0.18% (0.15% to 0.20%)                                                                                                                                         

  SBR                                                  98 000                 3905                                                3.98% (3.86% to 4.11%)                                                                                                                                         

  MEDPED                                               93 398                 789                                                 0.84% (0.79% to  0.90%)                                                                                                                                        

  Catapano *et al * (2016)[@R42]                       Multinational study†   DYSIS                                               2008--2013                 DLCN                  54 811                   45+                 24 884 (45.5%)    656           1.20% (1.11% to  1.29%)          ★★

  de Ferranti *et al *(2016)[@R43]                     USA                    NHANES                                              1999--2012                 DLCN                  36 949                   20+                 18 991 (51.4%)    146           0.40% (0.33% to  0.46%)          ★★★

  Guglielmi *et al *(2016)[@R55]                       Italy                  Health Longitudinal Patient Database                NR                         DLCN                  1 135 000                15+                 NR                2043          0.18% (0.17% to  0.19%)          ★★★

  Kalina *et al *(2001)[@R6]                           Hungary                Family doctors' registers                           1996--1998                 MEDPED                21 000                   NR                  NR                39            0.19% (0.13% to 0.25%)           ★★★

  Khera *et al *(2016)[@R10]                           Multinational study‡   MiGen Consortium\                                   NR                         DNA                   20 485                   NR                  3696 (26.2%)      24            0.12% (0.07% to  0.17%)          ★★
                                                                              CHARGE Consortium                                                                                                                                                                                                  

  LDL-C                                                1386                   6.77% (6.43% to 7.11%)                                                                                                                                                                                             

  Lahtinen *et al *(2015)[@R46]                        Finland                FINRISK Cohort                                      1992, 1997, 2002           DNA                   28 465                   25--74              14 501 (50.9%)    35            0.12% (0.09% to 0.17%)           ★★★

  Health 2000 Cohort                                   2000--2001             30+                                                                                                                                                                                                                

  Neil *et al *(2000)[@R7]                             United Kingdom         Simon Broome Register                               1980--1999                 SBR                   456 550                  20+                 231 796 (50.8%)   320           0.07% (0.06% to 0.08%)           ★★

  Pajak *et al *(2016)[@R44]                           Poland                 POL-MONICA Krakow                                   1983--1984\                DLCN                  37 889                   35--64              NR                153           0.40% (0.34% to 0.47%)           ★★★
                                                                                                                                  1987--1988\                                                                                                                                                    
                                                                                                                                  1992--1993                                                                                                                                                     

  POL-MONICA Warszawa                                  1984\                  35--64                                                                                                                                                                                                             
                                                       1988\                                                                                                                                                                                                                                     
                                                       1993                                                                                                                                                                                                                                      

  WOBASZ                                               2003--2004             20--74                                                                                                                                                                                                             

  Pilot HAPIEE                                         2001--2002             45--64                                                                                                                                                                                                             

  HAPIEE                                               2003--2005             45--70                                                                                                                                                                                                             

  NATPOL 2011                                          2011                   20--74                                                                                                                                                                                                             

  Perak *et al *(2016)[@R49]                           USA                    FHS                                                 1948                       LDL-C                 68 565                   30--62              19 693 (41.0%)    3850          5.62% (5.44% to 5.79%)           ★★

  FOS                                                  1971                   5--70                                                                                                                                                                                                              

  CARDIA                                               1985--1986             18--30                                                                                                                                                                                                             

  ARIC                                                 1987--1989             45--64                                                                                                                                                                                                             

  NHANES III---Mortality                               1988--1994             17--90                                                                                                                                                                                                             

  CHS                                                  1989--1990             65+                                                                                                                                                                                                                

  Safarova *et al *(2016)[@R56]                        USA                    Mayo ECH                                            1993--2014                 DLCN                  131 000                  18+                 77 290 (59.0%)    423           0.32% (0.29% to 0.35%)           ★★★

  Shi *et al *(2014)[@R53]                             China                  Jiangsu Nutrition Study                             2007                       DLCN                  9324                     20+                 5356 (57.4%)      26            0.28% (0.18% to 0.40%)           ★★★

  LDL-C                                                9280                                                                                                  44                    0.47% (0.34% to 0.62%)                                                                                        

  Steyn *et al *(1996)[@R47]                           South Africa           Random sample from south-western Cape               NR                         DNA                   1612                     15--64              809 (50.2%)       18            1.12% (0.66% to 1.69%)           ★★

  Vickery *et al *(2016)[@R57]                         Australia              General practitioners' offices in Perth             NR                         DLCN                  157 290                  18--70              NR                782           0.050% (0.46% to 0.53%)          ★★★

  Vuorio *et al *(1997)[@R48]                          Finland                Outpatient lipid clinic of North Karelia, Joensuu   1992--1996                 DNA                   180 000                  NR                  NR                407           0.23% (0.20% to 0.25%)           ★★★

  Watts *et al *(2015)[@R45]                           Australia              AusDiab                                             1999--2000                 DLCN                  18 222                   NR                  NR                81            0.44% (0.35% to 0.55%)           ★★

  Baker IDI                                            2005--2012                                                                                                                                                                                                                                

  **Studies reporting on FH prevalence in children**                                                                                                                                                                                                                                             

  de Ferranti *et al *(2016)[@R43]                     USA                    NHANES                                              1999--2012                 DLCN                  13 343                   12--19              NR                146           0.42% (0.32% to 0.54%)           ★★★

  Pang *et al *(2016)[@R51]                            Australia              Western Australia Pregnancy Cohort Study            1989--1991                 LDL-C                 2868                     14/17               770 (48.1%)       6             0.37% (0.12% to 0.74%)           ★

  Wald *et al *(2016)[@R58]                            United Kingdom         General Medical Practices                           2012--2015                 DNA                   10 095                   12.4--13.3 months   4882 (48.4%)      28            0.28% (0.18% to 0.39%)           ★★★

  Yang *et al *(2012)[@R50]                            Korea                  KNHANES IV                                          2007--2009                 LDL-C                 2363                     10--18              1118 (47.3%)      9             0.38% (0.17% to 0.68%)           ★★
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

★, weak; ★★, moderate; ★★★, strong.

\*95% CI not presented in articles but calculated from sample size and prevalence estimate.

†Austria, Belgium, Baltic states, Canada, China, Germany, Denmark, Egypt, France, Greece, United Arab Emirates, Israel, Ireland, Italy, Lebanon/Jordan, Netherlands, Norway, Portugal, Russia, Saudi, Slovakia, Slovenia, South Africa, Spain, Sweden, United Kingdom.

‡MiGen (ATVB, EOMI, JHS, Munich-MI, OHS, PROCARDIS, PROMIS): Canada, Germany, Italy, Pakistan, USA; CHARGE (ARIC, CHS, FHS, RBS, ERFS): Denmark, Netherlands, USA.

ARIC, Atherosclerotic Risk in Communities Study; ATVB, Atherosclerosis, Thrombosis, and Vascular Biology Italian Study; AusDiab, Australian Diabetes, Obesity and Lifestyle Study; Baker IDI, Baker IDI Heart and Diabetes Institute; CARDIA, Coronary Artery Risk Development in Young Adults Study; CHARGE, Cohorts for Heart and Ageing Research in Genomic Epidemiology; CHS, Cardiovascular Health Study; DLCN, Dutch Lipid Clinic Network; DYSIS, Dyslipidemia International Study; ECH, Employee & Community Health System; EHR, Electronic Health Records; EOMI, Exome Sequencing Project (Early-Onset Myocardial Infarction); ERFS, Erasmus Rucphen Family Study; FH, familial hypercholesterolaemia; FHS, Framingham Heart Study; FINRISK, Finnish Cardiovascular Risk Study; FOS, Framingham Offspring Study; HAPIEE,  Health, Alcohol and Psychosocial factors In Eastern Europe; JHS, Jackson Heart Study; KNHANES, Korean National Health and Nutrition Examination Survey; LDL-C, Low density lipoprotein cholestrol; MEDPED, Making Early Diagnosis to Prevent Early Death; MiGen, Myocaridal infarction Genetics; Munich-MI, Munich Myocardial Infarction Study; NATPOL, National Survey of Risk Factors for Cardiovascular Diseases; NHANES III, National Health and Nutrition Examination Survey III; NR, not reported; OHS, Ottawa Heart Study; POL-MONICA, Poland  MONItoring of trends and determinants of CArdiovascular disease; PROCARDIS, Precocious Coronary Artery Disease; PROMIS, Pakistan Risk of Myocardial Infarction Study; RBS, Rotterdam Baseline Study; SBR, Simon Broome Registry; WOBASZ, Wieloośrodkowe Ogólnopolskie BAdanie Stanu Zdrowia Ludności . 

Meta-analysis {#s3c}
-------------

### Overall pooled prevalence {#s3c1}

Nineteen estimates were included in the meta-analysis of overall prevalence, representing 2 458 456 unique individuals.[@R6] A further two studies reported data from cohorts represented by other studies within a shorter sampling frame, creating the potential for the overlap of cohorts.[@R11] These estimates were excluded to avoid overweighting a population. The overall random effects pooled prevalence of FH was 0.40% (95% CI 0.29% to 0.52%) ([figure 2](#F2){ref-type="fig"}).

![Forest plot of overall pooled prevalence (%) of heterozygous familial hypercholesterolaemia. I^2^, between-study heterogeneity; LCL, lower confidence limit; POP, population; PREV, prevalence; UCL, upper confidence limit; WGHT, weight under the random-effects model. Note: prevalence estimates were derived using the double-arcsine method, back-transformed and expressed as percentages for ease of interpretation.](bmjopen-2017-016461f02){#F2}

### Prevalence of FH in adults {#s3c2}

Sixteen prevalence estimates were included in the meta-analysis of adult prevalence, representing 2 431 053 unique individuals.[@R6] The overall random effects pooled prevalence of FH was 0.40% (95% CI 0.29% to 0.54%) (see online [supplementary etable 8](#SP1){ref-type="supplementary-material"}).

### Prevalence of FH in children {#s3c3}

Combining four studies (n=27 403) which reported FH prevalence estimates in individuals aged under 19 (see online [supplementary etable 9](#SP1){ref-type="supplementary-material"}), we calculated a pooled prevalence of 0.36% (95% CI 0.28% to 0.45%), with little heterogeneity (I^2^=13.32%).[@R43]

### Variation in prevalence by age {#s3c4}

Six studies[@R7] reported age-stratified data on the adult prevalence of FH, but only two of these presented data in forms amenable for pooled analysis ([figure 3](#F3){ref-type="fig"}).[@R7] All studies showed variation in FH frequency with age, with an increase in prevalence that peaked between ages 60 and 69 and declining thereafter, a trend reflected in our pooled estimates.

![Age-stratified pooled familial hypercholesterolaemia (FH) prevalence estimates and 95% CIs. [figure 3](#F3){ref-type="fig"}Error bars are representative of 95% CIs for each pooled estimate. Lower CIs are omitted; all cross 0%. I^2^, between-study heterogeneity; LCL, lower confidence limit; UCL, upper confidence limit.](bmjopen-2017-016461f03){#F3}

### Variation in prevalence by sex {#s3c5}

Nine studies presented prevalence figures by sex,[@R7] most of which reported similar FH frequencies between men and women. Our pooled prevalence estimates ([figure 4](#F4){ref-type="fig"}) were comparable between males (0.42%; 95% CI 0.18% to 0.75%; n=364 130) and females (0.45%; 95% CI 0.19% to 0.82%; n=319 726) (OR: 0.85; 95% CI 0.0.69 to 1.07; n=639 717).

![(A) Forest plot of pooled prevalence (%) of heterozygous FH in the male population. (B) Forest plot of pooled prevalence (%) of FH in the female adult population. (C) Forest plot of pooled OR of male:female FH prevalence. FH, familial hypercholesterolaemia; I^2^, between-study heterogeneity; LCL, lower confidence limit; POP, population; PREV, prevalence; UCL, upper confidence limit; WGHT, weight under the random-effects model. Note: prevalence estimates were derived using the double-arcsine method, back-transformed and expressed as percentages for ease of interpretation.](bmjopen-2017-016461f04){#F4}

### Variation in prevalence by geographic location {#s3c6}

When FH was analysed by continent ([figure 5](#F5){ref-type="fig"}), European (seven studies; n=1 957 002) and Asian studies (one study; n=9324) tended to report lower prevalence estimates than our overall pooled prevalence estimate, while North American (three studies; n=236 537) and Australasian (two studies; n=175 512) studies reported estimates comparable to it. The one study from South Africa (n=1612) reported a greater pooled FH prevalence than our pooled estimate, as did studies of international cohorts.

![Forest plot of overall pooled prevalence (%) of heterozygous familial hypercholesterolaemia stratified by population geography. I^2^, between-study heterogeneity; LCL, lower confidence limit; POP, population; PREV, prevalence; UCL, upper confidence limit; WGHT, weight under the random-effects model. Note: prevalence estimates were derived using the double-arcsine method, back-transformed and expressed as percentages for ease of interpretation.](bmjopen-2017-016461f05){#F5}

### Variation in prevalence by diagnostic criteria {#s3c7}

Frequencies from studies in the DNA-based analysis subgroup were comparable to the pooled prevalence estimate (0.40%; 95% CI 0.24% to 0.58%) while DLCN (0.46%; 95% CI 0.25% to 0.70%) and LDL-C-based estimates (0.45%; 95% CI 0.34% to 0.57%) tended to report slightly higher frequencies (see online [supplementary efigure 1](#SP1){ref-type="supplementary-material"}). Of two studies exclusively using SBR[@R7] or MEDPED[@R6] criteria, both reported lower frequencies than our pooled prevalence estimate.

### Variation in prevalence by study quality {#s3c8}

When stratified by study quality ratings, studies rated strong had a lower estimate of FH prevalence with greater precision (0.33%; 95% CI 0.24% to 0.43%) than studies rated moderate in quality (0.75%; 95% CI 0.29% to 1.29%) or low quality (0.37%, 95% CI 0.12% to 0.74%) (see online [supplementary efigure 2](#SP1){ref-type="supplementary-material"}).

### Meta-regression analyses {#s3c9}

Considerable heterogeneity existed between studies (I^2^: 99.34%; 95% CI 99.24% to 99.44%). The results of eight meta-regression analyses ([table 2](#T2){ref-type="table"}) showed little evidence of an effect of age (p=0.79), sex (p=0.17), sample size (p*=*0.06), diagnostic criteria (p=0.23), study setting (p=0.50), quality (p=0.82) or year of publication (p=0.52) on our pooled prevalence estimate. Joint meta-regression tests showed significant differences in prevalence estimates among categories of studies when stratified by geographical location (p=0.04). Major asymmetry was present in both Begg's funnel plot and the Doi plot (see online [supplementary efigure 3](#SP1){ref-type="supplementary-material"}) and the results of Egger's test suggested that publication bias may have been present (p\<0.001).[@R59] When we used the trim and fill method to control for publication bias, nine additional studies were generated with estimates comparable to or lower than our pooled prevalence estimate, bringing the pooled prevalence of FH to 0.20% (95% CI 0.10% to 0.40%).

###### 

Meta-regression analyses for pooled estimate of familial hypercholesterolaemia prevalence

  Covariate                 Observations   Coefficient    95% CI                        p Value   Adjusted R^2^ (%)   I^2^ residual (%)
  ------------------------- -------------- -------------- ----------------------------- --------- ------------------- -------------------
  Age                       11             8.26×10^−3^    −0.06 to 0.08                 0.79      −10.29              99.65
  Diagnostic criteria       15             NA             NA                            0.23      12.77               99.45
  Geographical location\*   19             NA             NA                            0.04      75.92               99.00
  Sex                       13             −4.07          −10.18 to 2.00                0.17      8.99                99.67
  Sample size               19             −1.21×10^−6^   −2.47×10^−6^ to 3.66×10^−8^   0.06      4.20                100.00
  Study quality             19             0.02           −0.16 to 0.20                 0.82      −5.64               99.54
  Study setting             19             0.24           −0.49 to 0.96                 0.50      −2.65               99.28
  Year of publication       19             0.16           −0.04 to 0.07                 0.52      −2.54               99.41

\*p\<0.05.

Adjusted R^2^, proportion of between-study variance explained with Knapp-Hartung modification; I^2^ residual, per cent residual variation due to heterogeneity; NA, not applicable; Observations, number of studies with observations included in the meta-regression model.

### Sensitivity analyses {#s3c10}

Pooled prevalence estimates were broadly consistent in seven sensitivity analyses (see online [supplementary etable 10](#SP1){ref-type="supplementary-material"}). Studies estimating FH prevalence in patient cohorts (0.33%; 95% CI 0.21% to 0.47%) tended to report lower frequencies than those in large population-based samples (0.45%; 95% CI 0.26% to 0.68%). Heterogeneity of these estimates was significant and comparable (\>99%).

Discussion {#s4}
==========

Our meta-analysis of 19 cohort studies including 2 458 456 unique individuals found an FH prevalence of 0.40% in the general population. This suggests that as many as 1 in 250 individuals may be affected by FH (95% CI 1 in 345 to 1 in 192), equating to nearly 30 million people worldwide.[@R60] This is a higher frequency than observed in prior reports and supports current thinking that FH is underdiagnosed, and thus likely undertreated in the general population.[@R61] This is further supported by sensitivity analyses in which patient cohort studies were found to report lower prevalence estimates than those using large population databases.

Interestingly, we detected a slightly lower prevalence of FH in those aged 0--19 (1 in 278; 95% CI 1 in 345 to 1 in 222). Further, FH prevalence tended to increase with age. This trend runs counterintuitively to expectations given that FH is a genetic condition with a high risk of CVD-related mortality---frequency estimates should be comparable in adults and children save for age-related declines in prevalence associated with premature mortality. Our findings may be explained by insufficient dyslipidaemia screening in children and adolescents.[@R62] Indeed, follow-up data from the Simon Broome FH registry, following more than 300 000 patients found that only a quarter of affected patients received diagnoses by middle age, with the highest rates of underdiagnosis among children and adolescents.[@R7] However, LDL-C levels also rise with age, making it likely for older individuals to be diagnosed using established clinical criteria. It remains possible that the disparity in prevalence may be due to the inability of population-based studies to account for age-related increases in LDL-C and the reduced sensitivity this confers in detecting FH.[@R65]

Our finding that FH affects males and females equally has important implications. Many cases of FH are diagnosed following the first cardiac event, which has a later onset for women relative to men.[@R27] This makes it possible that women with FH may go unrecognised for longer. Yet, more women may be expected to qualify for diagnosis using clinical characteristics at later ages, primarily due to the delayed onset of coronary artery disease. Whether delayed FH detection in women relative to men confers poorer clinical outcomes has yet to be formally explored in the literature. However, one of our included studies observed that after age 60, higher proportions of women met criteria for an FH diagnosis, suggesting that many men with FH had died at an earlier age.[@R11] Identifying sex-related differences in FH presentation may allow for earlier FH diagnosis and represents an important clinical priority. New diagnostic criteria developed through improved use of routinely collected health data may make this possible.[@R66]

We also found lower prevalence reports in Europe relative to regions elsewhere. Thus far, much of the regional variation in FH prevalence has been attributed to the presence of founder populations. Founder effects occur when subpopulations are formed by the immigration of 'founder subjects', leading to a higher proportion of individuals who share a mutation in subsequent generations due to genetic drift.[@R13] Though influenced by a predominance of European studies, our review suggests the potential for variations in FH frequency between countries extending beyond founder effects. This is important given that for many of the world's countries, rates of FH still remain unknown. This includes North America, where studies from USA comprise the evidence base for ascertaining study prevalence. CVD remains the leading cause of death worldwide[@R67] and, left untreated, nearly 85% of males and 50% of females with FH are expected to suffer coronary events prior to age 65.[@R27] Thus, greater efforts should be made to explore region-specific frequencies of FH prevalence and more accurately characterise disease burden. Accurate prevalence estimates, augmented by recent big data approaches and the introduction of *International Classification of Diseases, 10th Revision* codes for FH should facilitate increased awareness and improved management.

How FH should be identified remains an area of continued debate. A number of organisations have recommended universal lipid screening in childhood as a strategy to identify FH.[@R68] However, a recent report by the US Preventive Services Task Force concluded that there was 'inadequate direct evidence on the benefit of screening for FH'.[@R71] In addition, these programmes come with the added risks of potential overdiagnosis, fiscal and non-fiscal health system burden and adverse psychosocial impacts for children and families.[@R71] As an alternative, some European countries have developed genetic FH screening strategies. However, such programmes are neither currently universally accessible nor deemed to be cost-effective.[@R8] DNA-based identification may also fail to capture individuals with undiscovered mutations or those with polygenic forms of FH that still demonstrate the clinical phenotype.[@R72] Finally, the diagnostic accuracy of these programmes has been challenged by findings that up to 30% of estimated cases may not be identified in countries with some of the most robust screening programmes, due to lack of index cases to inform cascade screening.[@R73] In light of these limitations, the high degree of concordance between our pooled prevalence estimates derived through DLCN and DNA-based analyses are clinically important. Due to a simplified approach---facilitated by the use of readily observable clinic characteristics and biochemical parameters---DLCN criteria may facilitate the more ready identification of patients affected by FH in primary care. Though other clinical criteria may have comparable clinical utility, our study currently provides insufficient evidence in strong support of them. Regardless, improving the identification of FH and mitigating CVD and mortality requires a multifaceted approach involving clinical, biochemical and genetic parameters.

These findings provide new insights into FH prevalence. Yet, they should be interpreted in light of some important limitations. First, despite an extensive search strategy, we included only peer-reviewed English language studies indexed in six online databases and it remains possible that other relevant studies went unpublished or were indexed in other languages, in print repositories or within the grey literature.[@R74] Second, we did not contact study authors for additional data or clarifications of their published studies. While this was counterbalanced in part by the use of a tool with high inter-rater agreement for quality assessment,[@R75] agreement levels between reviewers and authors have yet to be explored with the EPHPP tool. Third, while geographical location of our included studies was significantly associated with variance in FH prevalence, our analyses possessed a considerable amount of between-study heterogeneity, the majority of which remains unexplained. This may be attributed to limited power in our meta-regression analyses due to small numbers of observations.[@R38] In which case, our subgroup analyses provide more credible insight into the sociodemographic variation of FH prevalence though even these are limited by the lack of interaction tests in our subgroup analyses. It is important to note that the high degree of heterogeneity in our meta-analyses does not imply imprecision in our prevalence estimate.[@R38] Indeed, a key strength of our study is its sample size and the greater power and precision it conferred to our analyses. The heterogeneity between studies are thus more likely reflective of real differences in study populations, designs and outcome measurements.[@R36] This heterogeneity was anticipated and accommodated for through random effects meta-analysis.

Conclusion {#s5}
==========

Our systematic review found that FH currently affects 1 in 250 people in the adult population. While FH affects males and females equally, regional and age-specific variations exist in FH frequency. With the range of treatment options available for this condition increased, particularly with the recent advent of PCKS9 inhibitors, greater efforts should be made to identify individuals who could stand to benefit from therapy.
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